COLL Quote, Financials, Valuation and Earnings

Altimmune, Inc. has a net margin of 15.05% compared to Collegium Pharmaceutical, Inc.'s net margin of -380280%. Collegium Pharmaceutical, Inc.'s return on equity of 24.26% beat Altimmune, Inc.'s return on equity of -56.24%.

Collegium Pharmaceutical, Inc. has a consensus price target of $48.67, signalling downside risk potential of -0.36%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.75 which suggests that it could grow by 328.74%. Given that Altimmune, Inc. has higher upside potential than Collegium Pharmaceutical, Inc., analysts believe Altimmune, Inc. is more attractive than Collegium Pharmaceutical, Inc..

Collegium Pharmaceutical, Inc. has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of -0.029, suggesting its less volatile than the S&P 500 by 102.89%.

Collegium Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.

Collegium Pharmaceutical, Inc. quarterly revenues are $209.4M, which are larger than Altimmune, Inc. quarterly revenues of $5K. Collegium Pharmaceutical, Inc.'s net income of $31.5M is higher than Altimmune, Inc.'s net income of -$19M. Notably, Collegium Pharmaceutical, Inc.'s price-to-earnings ratio is 30.36x while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical, Inc. is 2.44x versus 15,865.35x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals, Inc. has a net margin of 15.05% compared to Collegium Pharmaceutical, Inc.'s net margin of 35.57%. Collegium Pharmaceutical, Inc.'s return on equity of 24.26% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.

Collegium Pharmaceutical, Inc. has a consensus price target of $48.67, signalling downside risk potential of -0.36%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.86 which suggests that it could grow by 43.86%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Collegium Pharmaceutical, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Collegium Pharmaceutical, Inc..

Collegium Pharmaceutical, Inc. has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.5%.

Collegium Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Collegium Pharmaceutical, Inc. quarterly revenues are $209.4M, which are larger than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. Collegium Pharmaceutical, Inc.'s net income of $31.5M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, Collegium Pharmaceutical, Inc.'s price-to-earnings ratio is 30.36x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 14.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical, Inc. is 2.44x versus 5.32x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of 15.05% compared to Collegium Pharmaceutical, Inc.'s net margin of --. Collegium Pharmaceutical, Inc.'s return on equity of 24.26% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Collegium Pharmaceutical, Inc. has a consensus price target of $48.67, signalling downside risk potential of -0.36%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 156.49%. Given that Viking Therapeutics, Inc. has higher upside potential than Collegium Pharmaceutical, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Collegium Pharmaceutical, Inc..

Collegium Pharmaceutical, Inc. has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

Collegium Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Collegium Pharmaceutical, Inc. quarterly revenues are $209.4M, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Collegium Pharmaceutical, Inc.'s net income of $31.5M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Collegium Pharmaceutical, Inc.'s price-to-earnings ratio is 30.36x while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical, Inc. is 2.44x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 15.05% compared to Collegium Pharmaceutical, Inc.'s net margin of 34.76%. Collegium Pharmaceutical, Inc.'s return on equity of 24.26% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Collegium Pharmaceutical, Inc. has a consensus price target of $48.67, signalling downside risk potential of -0.36%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $489.04 which suggests that it could grow by 6.5%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than Collegium Pharmaceutical, Inc., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than Collegium Pharmaceutical, Inc..

Collegium Pharmaceutical, Inc. has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Collegium Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Collegium Pharmaceutical, Inc. quarterly revenues are $209.4M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Collegium Pharmaceutical, Inc.'s net income of $31.5M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Collegium Pharmaceutical, Inc.'s price-to-earnings ratio is 30.36x while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical, Inc. is 2.44x versus 10.14x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.